Your browser doesn't support javascript.
loading
Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.
Tse, C S; Loftus, E V; Raffals, L E; Gossard, A A; Lightner, A L.
Affiliation
  • Tse CS; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Loftus EV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Raffals LE; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Gossard AA; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Lightner AL; Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Aliment Pharmacol Ther ; 48(5): 578-579, 2018 09.
Article in En | MEDLINE | ID: mdl-30156321
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cholangitis, Sclerosing / Inflammatory Bowel Diseases Limits: Humans Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2018 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cholangitis, Sclerosing / Inflammatory Bowel Diseases Limits: Humans Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2018 Type: Article Affiliation country: United States